[go: up one dir, main page]

WO2009072628A1 - ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体 - Google Patents

ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体 Download PDF

Info

Publication number
WO2009072628A1
WO2009072628A1 PCT/JP2008/072198 JP2008072198W WO2009072628A1 WO 2009072628 A1 WO2009072628 A1 WO 2009072628A1 JP 2008072198 W JP2008072198 W JP 2008072198W WO 2009072628 A1 WO2009072628 A1 WO 2009072628A1
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
binding
monoclonal antibody
heparin
antibody capable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/072198
Other languages
English (en)
French (fr)
Inventor
Eisuke Mekada
Ryo Iwamoto
Shingo Miyamoto
Kenya Shitara
Akiko Furuya
Kazuyasu Nakamura
Kumiko Takahashi
Hiroshi Ando
Kazuhiro Masuda
Yuka Sasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Priority to AU2008332296A priority Critical patent/AU2008332296A1/en
Priority to CA2707689A priority patent/CA2707689A1/en
Priority to JP2009544756A priority patent/JP5532401B2/ja
Priority to EP08857234A priority patent/EP2221374A4/en
Priority to CN2008801262682A priority patent/CN101978054B/zh
Publication of WO2009072628A1 publication Critical patent/WO2009072628A1/ja
Priority to US12/609,434 priority patent/US8163282B2/en
Anticipated expiration legal-status Critical
Priority to US13/428,787 priority patent/US20130337505A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

　ＨＢ－ＥＧＦが亢進する疾患を治療するための医薬が求められている。本発明によれば、細胞膜に結合しているＨＢ－ＥＧＦ、膜型ＨＢ－ＥＧＦおよび分泌型ＨＢ－ＥＧＦに結合するモノクローナル抗体およびその抗体断片が提供することができる。
PCT/JP2008/072198 2007-12-05 2008-12-05 ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体 Ceased WO2009072628A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2008332296A AU2008332296A1 (en) 2007-12-05 2008-12-05 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
CA2707689A CA2707689A1 (en) 2007-12-05 2008-12-05 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
JP2009544756A JP5532401B2 (ja) 2007-12-05 2008-12-05 ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体
EP08857234A EP2221374A4 (en) 2007-12-05 2008-12-05 MONOCLONAL ANTIBODY CAPABLE OF BINDING TO A GROWTH FACTOR OF HB-EGF (HEPARIN-BINDING EPIDERMAL GROWTH FACTOR)
CN2008801262682A CN101978054B (zh) 2007-12-05 2008-12-05 能够与肝素结合性表皮生长因子样生长因子结合的单克隆抗体
US12/609,434 US8163282B2 (en) 2007-12-05 2009-10-30 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
US13/428,787 US20130337505A1 (en) 2007-12-05 2012-03-23 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-315068 2007-12-05
JP2007315068 2007-12-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/609,434 Continuation US8163282B2 (en) 2007-12-05 2009-10-30 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor

Publications (1)

Publication Number Publication Date
WO2009072628A1 true WO2009072628A1 (ja) 2009-06-11

Family

ID=40717806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/072198 Ceased WO2009072628A1 (ja) 2007-12-05 2008-12-05 ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体

Country Status (8)

Country Link
US (2) US8163282B2 (ja)
EP (1) EP2221374A4 (ja)
JP (1) JP5532401B2 (ja)
KR (1) KR20100097674A (ja)
CN (1) CN101978054B (ja)
AU (1) AU2008332296A1 (ja)
CA (1) CA2707689A1 (ja)
WO (1) WO2009072628A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021381A1 (ja) * 2009-08-17 2011-02-24 株式会社未来創薬研究所 抗hb-egf抗体を有効成分として含む医薬組成物
WO2013140335A1 (fr) 2012-03-20 2013-09-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibiteur de l'hb-egf dérivé du domaine r de la toxine diphtérique pour le traitement des maladies associées a l'activation de la voie hb-egf/egfr
WO2014174596A1 (ja) * 2013-04-23 2014-10-30 株式会社医学生物学研究所 ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
US9023993B2 (en) 2006-10-20 2015-05-05 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
JP5806935B2 (ja) * 2009-08-17 2015-11-10 中外製薬株式会社 抗ｈｂ−ｅｇｆ抗体を有効成分として含む医薬組成物
JP5838427B2 (ja) * 2013-04-23 2016-01-06 株式会社医学生物学研究所 ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
WO2025012415A1 (en) 2023-07-12 2025-01-16 Commissariat A L'energie Atomique Et Aux Energies Alternatives Combination of a hb-egf inhibitor and a corticosteroid agent for the treatment of kidney diseases associated with activation of the hb-egf/egfr pathway

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2039704A4 (en) 2006-06-06 2010-04-21 Kyowa Hakko Kirin Co Ltd MONOCLONAL ANTIBODY CAPABLE OF BINDING TO EPIDERMAL GROWTH FACTOR GROWTH FACTOR BINDING TO HEPARIN
WO2010090222A1 (ja) * 2009-02-04 2010-08-12 国立大学法人大阪大学 Ｈｂ－ｅｇｆ結合性タンパク質複合体
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
JP7358367B2 (ja) * 2017-10-24 2023-10-10 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ１抗体およびその使用
WO2020006449A1 (en) 2018-06-29 2020-01-02 Go Therapeutics, Inc. Anti-glyc0-muc1 antibodies and their uses
CN109580959B (zh) * 2018-12-17 2020-03-31 江苏莱森生物科技研究院有限公司 一种检测肝素结合性表皮生长因子的elisa试剂盒
CN118027211A (zh) * 2024-04-11 2024-05-14 上海惠盾因泰生物科技有限公司 一种识别重组egf-crm197疫苗的单克隆抗体及其应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
JPS60221091A (ja) 1983-12-21 1985-11-05 Kyowa Hakko Kogyo Co Ltd 新規プロモ−タ−
JPS61178926A (ja) 1984-03-06 1986-08-11 Takeda Chem Ind Ltd 化学修飾ペプチドホルモンおよびその製造法
JPS63299A (ja) 1986-04-22 1988-01-05 イミユネツクス・コ−ポレ−シヨン ヒトｇ−ｃｓｆタンパク質の発現
JPH02117920A (ja) 1988-05-06 1990-05-02 Sumitomo Pharmaceut Co Ltd ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US4939094A (en) 1985-08-28 1990-07-03 Kyowa Hakko Kogyo Co., Ltd. Fused antigen polypeptide
JPH02227075A (ja) 1988-09-29 1990-09-10 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JPH05336963A (ja) 1991-12-17 1993-12-21 Kyowa Hakko Kogyo Co Ltd 新規α２→３シアリルトランスフェラーゼ
WO1994023021A1 (fr) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
WO1997010354A1 (fr) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
US20040253234A1 (en) 2001-06-28 2004-12-16 Kenya Shitara Humanized antibody against fibroblast growth factor-8 and antibody fragment thereof
WO2007142277A1 (ja) * 2006-06-06 2007-12-13 Kyowa Hakko Kirin Co., Ltd. ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5676849B2 (ja) * 2006-10-20 2015-02-25 中外製薬株式会社 抗ｈｂ−ｅｇｆ抗体を有効成分として含む癌治療剤
EP3040347A3 (en) * 2006-10-20 2016-09-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
US4686191A (en) 1981-12-25 1987-08-11 Hakko Kogyo Co., Ltd. Kyowa Recombinant plasmid containing human interferon-beta gene
JPS60221091A (ja) 1983-12-21 1985-11-05 Kyowa Hakko Kogyo Co Ltd 新規プロモ−タ−
JPS61178926A (ja) 1984-03-06 1986-08-11 Takeda Chem Ind Ltd 化学修飾ペプチドホルモンおよびその製造法
US4939094A (en) 1985-08-28 1990-07-03 Kyowa Hakko Kogyo Co., Ltd. Fused antigen polypeptide
JPS63299A (ja) 1986-04-22 1988-01-05 イミユネツクス・コ−ポレ−シヨン ヒトｇ−ｃｓｆタンパク質の発現
JPH02117920A (ja) 1988-05-06 1990-05-02 Sumitomo Pharmaceut Co Ltd ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
JPH02227075A (ja) 1988-09-29 1990-09-10 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
US5160735A (en) 1989-06-19 1992-11-03 Kyowa Hakko Kogyo Co. Ltd. Plasminogen activator
JPH05336963A (ja) 1991-12-17 1993-12-21 Kyowa Hakko Kogyo Co Ltd 新規α２→３シアリルトランスフェラーゼ
WO1994023021A1 (fr) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
WO1997010354A1 (fr) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
US20040253234A1 (en) 2001-06-28 2004-12-16 Kenya Shitara Humanized antibody against fibroblast growth factor-8 and antibody fragment thereof
WO2007142277A1 (ja) * 2006-06-06 2007-12-13 Kyowa Hakko Kirin Co., Ltd. ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体

Non-Patent Citations (134)

* Cited by examiner, † Cited by third party
Title
"Funakoshi Sogo Catalog 2005-2006 Shiyakuhen [Kotai]", 22 December 2005, pages: 474 *
AGRIC. BIOL. CHEM., vol. 53, 1989, pages 277
AGRICULTURAL BIOLOGICAL CHEMISTRY, vol. 48, 1984, pages 669
AM. J PATHOL., vol. 143, 1993, pages 784 - 793
ARTERIOSCLER. THROMB. VASC. BIOL., vol. 16, 1996, pages 1524 - 1531
BIO/TECHNOLOGY, vol. 10, no. 16, 1992, pages 3 - 167
BIO/TECHNOLOGY, vol. 2, 1991, pages 266 - 271
BIO/TECHNOLOGY, vol. 9, 1991, pages 266 - 271
BIOCHEM BIOPHYS, RES. COMMUN., vol. 198, 1994, pages 25 - 31
BIOCHEM. BIOPHYS. ACTA, vol. 1333, 1997, pages F179
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 149, 1987, pages 960 - 968
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 202, 1994, pages 1705
BLOOD, vol. 65, 1985, pages 1349
BRAIN RES., vol. 827, 1999, pages 130 - 138
BREAST CANCER RES. TREAT., vol. 67, 2001, pages 81
CANCER RES., vol. 46, 1986, pages 6489
CANCER RES., vol. 52, 1992, pages 3402
CANCER RES., vol. 56, 1996, pages 1118
CANCER RES., vol. 61, 2001, pages 6227
CANCER RES., vol. 64, 2004, pages 5283
CANCER RES., vol. 64, 2004, pages 5720
CELL, vol. 33, 1983, pages 717 - 728
CELL, vol. 41, 1985, pages 479 - 487
CELL, vol. 69, 1992, pages 1051
CLIN. CANCER RES., vol. 11, 2005, pages 4639
CLIN. CANCER RES., vol. 11, 2005, pages 4783
COHEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 69, 1972, pages 2110
CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 18, 1978, pages 1 - 7
CYTOKINE GROWTH FACTOR REV., vol. 11, 2000, pages 335
CYTOTECHNOL., vol. 1, 1990, pages 173 - 180
CYTOTECHNOL., vol. 3, 1990, pages 133 - 140
CYTOTECHNOLOGY, vol. 3, 1990, pages 133
CYTOTECHNOLOGY, vol. 3, 1990, pages 133 - 140
CYTOTECHNOLOGY, vol. J, 1990, pages 133
DNA CLONING: A PRACTICAL APPROACH, vol. 1, 1985, pages 49
EMB O J, vol. 20, 2001, pages 3342 - 3350
EMBO J, vol. 16, 1997, pages 1268 - 1278
EUROPEAN J IMMUNOLOGY, vol. 2, 1976, pages 511 - 519
GENE, vol. 17, 1982, pages 107
GENE, vol. 27, 1984, pages 223 - 232
GENE, vol. 33, 1985, pages 103 - 119
GENE, vol. 34, 1985, pages 315
GENE, vol. 38, 1985, pages 275 - 276
GENES DEVELOP., vol. 4, 1990, pages 1288
GENETICS, vol. 59, 1968, pages 177 - 190
GENOME RES., vol. 7, 1997, pages 649, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/Education/BLASTinformation3.html>
HEPATOLOGY, vol. 22, 1995, pages 1584 - 1590
HUMAN ANTIBODIES & HYBRIDOMAS, vol. 5, 1994, pages 48 - 56
HUMAN ANTIBODIES HYBRIDOMAS, vol. 5, 1994, pages 48
HYBRIDOMA, vol. 17, 1998, pages 559 - 567
IMMUNOL., vol. 85, 1995, pages 668
INT. J. CANCER, vol. 98, 2002, pages 505
J BIOL. CHEM., vol. 267, 1992, pages 6205 - 6212
J BIOL. CHEM., vol. 269, 1994, pages 20060 - 20066
J BIOL. CHEM., vol. 271, 1996, pages 2966
J BIOL. CHEM., vol. 277, 2002, pages 37487 - 37491
J CELL BIOL., vol. 128, 1995, pages 929 - 938
J CELL BIOL., vol. 129, 1995, pages 1691 - 1705
J CELL BIOL., vol. 151, 2000, pages 209 - 219
J HISTOCHEM. CYTOCHEM, vol. 49, 2001, pages 439
J IMMUNOLOGY, vol. 123, 1979, pages 1548 - 1550
J MOL. BIOL., vol. 215, 1990, pages 403
J PATHOL., vol. 189, 1999, pages 431 - 438
J. BIOCHEM., vol. 101, 1987, pages 1307 - 1310
J. BIOCHEMISTRY, vol. 101, 1987, pages 1307
J. BIOL. CHEM., vol. 270, 1995, pages 1015
J. CLIN. INVEST., vol. 95, 1995, pages 404
J. CLIN.ONCOL., vol. 2, 1984, pages 881
J. IMMUNOL., vol. 144, 1990, pages 1382
J. OF CELL BIOLOGY, vol. 163, 2003, pages 469
J.IMMUNOL., vol. 135, 1985, pages 1530
J.NATL.CANCER INST., vol. 80, 1988, pages 932
J.NATL.CANCER INST., vol. 80, 1988, pages 937
J.NUCL.MED., vol. 26, 1985, pages 1011
JOURNAL OF BIOTECHNOLOGY, vol. 23, 1992, pages 271 - 289
JOURNAL OF IMMUNOLOGICAL METHODS, vol. 167, 1994, pages 271 - 278
JOURNAL OF MOLECULAR BIOLOGY, vol. 112, 1977, pages 535 - 542
JOURNAL OF MOLECULAR BIOLOGY, vol. 16, 1966, pages 118 - 133
JOURNAL OF MOLECULAR BIOLOGY, vol. 166, 1983, pages 1 - 19
JOURNAL OF MOLECULAR BIOLOGY, vol. 215, 1990, pages 403 - 410
LOWE ET AL., PROC. NATL. ACAD SCI. USA, vol. 86, 1989, pages 8227
MCCARTHY, S. A. ET AL.: "Rapid induction of heparin-binding epidermal growth factor/ diphtheria toxin receptor expression by Raf and Ras oncogenes.", GENES AND DEVELOPMENT, vol. 9, 1995, pages 1953 - 1964 *
MEKADA ET AL., J BIO. CHEM., vol. 272, 1997, pages 27084 - 27090
METHODS IN ENZYMOLOGY, vol. 154, 1987, pages 3 - 28
METHODS IN ENZYMOLOGY, vol. 183, 1990, pages 63
MIYAMOTO, S. ET AL.: "Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy.", CANCER SCI., vol. 97, no. 5, May 2006 (2006-05-01), pages 341 - 347 *
MOLECULAR & GENERAL GENETICS, vol. 168, 1979, pages 111
MOLECULAR &CELLULAR BIOLOGY, vol. 3, 1983, pages 280 - 289
MOLECULAR IMMUNOL., vol. 32, 1995, pages 249
NAT, MED., vol. 8, 2002, pages 35
NAT. REV. DRUG. DISCOV., vol. 2, 2003, pages 52 - 62
NATURE BIOTECHNOL., vol. 15, 1997, pages 629
NATURE, vol. 227, 1970, pages 680 - 685
NATURE, vol. 256, 1975, pages 495 - 497
NATURE, vol. 276, 1978, pages 269 - 270
NATURE, vol. 322, 1988, pages 323
NATURE, vol. 329, 1987, pages 840
NATURE, vol. 402, 1999, pages 884
NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389
NUCLEIC ACIDS RESEARCH, vol. 10, 1982, pages 6487
NUCLEIC ACIDS RESEARCH, vol. 13, 1985, pages 4431
NUCLEIC ACIDS RESEARCH, vol. 17, 1989, pages 9494
ONCOL. REP., vol. 8, 2001, pages 903
PAULSON ET AL., J BIOL. CHEM., vol. 264, 1989, pages 17619
PNAS, vol. 100, 2003, pages 3221
PNAS, vol. 100, no. 100, 2003, pages 3221 - 3226
PROC. NALL ACAD. SCI. USA, vol. 79, 1982, pages 6409
PROC. NATL. ACAD SCI. U.S.A., vol. 90, 1993, pages 3889 - 3893
PROC. NATL. ACAD. SCI USA, vol. 82, 1985, pages 488
PROC. NATL. ACAD. SCI. USA, vol. 69, 1972, pages 2110
PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 4306
PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488
PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413
PROC. NATL. ACAD. SCI., USA, vol. 79, 1982, pages 6409
PROC.NATL.ACAD.SCI. USA, vol. 82, 1985, pages 1242
PROCEEDING OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 73, 1950, pages 1
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 74, 1977, pages 5463 - 5467
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 77, 1980, pages 4216 - 4220
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 78, 1981, pages 1527 - 1531
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 84, 1987, pages 7413 - 7417
PROTEIN ENGINEERING, vol. 1, 1994, pages 697
PROTEIN ENGINEERING, vol. 7, 1994, pages 697 - 704
PROTEIN ENGINEERING, vol. Z, 1994, pages 1501 - 1507
REITER ET AL., PROTEIN ENGINEERING, vol. 1, 1994, pages 697 - 704
SCIENCE, vol. 122, 1952, pages 501
SCIENCE, vol. 222, 1983, pages 778 - 782
SCIENCE, vol. 240, 1988, pages 1041 - 1043
SCIENCE, vol. 242, 1988, pages 423
SCIENCE, vol. 251, 1991, pages 936
See also references of EP2221374A4
STRATEGIES, vol. 5, 1992, pages 58 - 61
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519
VIROLOGY, vol. 8, 1959, pages 396
YOTSUMOTO, F. ET AL.: "Validation of HB-EGF and amphiregulin as targets for human cancer therapy.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 365, 20 November 2007 (2007-11-20), pages 555 - 561 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
US9023993B2 (en) 2006-10-20 2015-05-05 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
WO2011021381A1 (ja) * 2009-08-17 2011-02-24 株式会社未来創薬研究所 抗hb-egf抗体を有効成分として含む医薬組成物
CN102574917A (zh) * 2009-08-17 2012-07-11 株式会社未来创药研究所 含有抗hb-egf抗体作为有效成分的药物组合物
JP5806935B2 (ja) * 2009-08-17 2015-11-10 中外製薬株式会社 抗ｈｂ−ｅｇｆ抗体を有効成分として含む医薬組成物
WO2013140335A1 (fr) 2012-03-20 2013-09-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibiteur de l'hb-egf dérivé du domaine r de la toxine diphtérique pour le traitement des maladies associées a l'activation de la voie hb-egf/egfr
WO2014174596A1 (ja) * 2013-04-23 2014-10-30 株式会社医学生物学研究所 ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
WO2014175160A1 (ja) * 2013-04-23 2014-10-30 株式会社医学生物学研究所 ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
JP5838427B2 (ja) * 2013-04-23 2016-01-06 株式会社医学生物学研究所 ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
US9920117B2 (en) 2013-04-23 2018-03-20 Medical & Biological Laboratives Co., Ltd. Functional monoclonal antibody against heparin-binding epidermal growth factor-like growth factor
WO2025012415A1 (en) 2023-07-12 2025-01-16 Commissariat A L'energie Atomique Et Aux Energies Alternatives Combination of a hb-egf inhibitor and a corticosteroid agent for the treatment of kidney diseases associated with activation of the hb-egf/egfr pathway

Also Published As

Publication number Publication date
JPWO2009072628A1 (ja) 2011-04-28
EP2221374A1 (en) 2010-08-25
JP5532401B2 (ja) 2014-06-25
CN101978054B (zh) 2013-05-29
CA2707689A1 (en) 2009-06-11
AU2008332296A1 (en) 2009-06-11
EP2221374A4 (en) 2011-01-19
CN101978054A (zh) 2011-02-16
US8163282B2 (en) 2012-04-24
US20130337505A1 (en) 2013-12-19
US20110034673A1 (en) 2011-02-10
KR20100097674A (ko) 2010-09-03

Similar Documents

Publication Publication Date Title
WO2009072628A1 (ja) ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体
MX2010003380A (es) Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina.
WO2010145792A8 (en) Bispecific antigen binding proteins
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
AU2009260320A8 (en) Antibodies to IL-6 and their uses
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
MX2012007340A (es) Anticuerpos anti/her3 y usos de los mismos.
WO2011050106A3 (en) Anti-cd3 antibody dosing in autoimmune disease
WO2006084264A3 (en) Cd20 antibody variants and uses thereof
IL206108A (en) Antibody @ Bi-value @ Bi-specific L @ method for its preparation, compounds containing it @ and cell @ surrogate
EP3184546B8 (en) Human cgrp receptor binding antibodies
WO2007080392A3 (en) Ligands that have binding specificity for vegf and/or egfr and methods of use therefor
NZ592473A (en) Urinary biomarkers for predicting long-term dialysis
WO2010066803A3 (en) Human antibodies against human tissue factor
WO2008003103A3 (en) Novel multivalent immunoglobulins
CL2014000699A1 (es) Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco.
WO2010102251A3 (en) Il-17 binding proteins
NZ596711A (en) Dual variable domain immunoglobulins and uses thereof
EP2039704A4 (en) MONOCLONAL ANTIBODY CAPABLE OF BINDING TO EPIDERMAL GROWTH FACTOR GROWTH FACTOR BINDING TO HEPARIN
MX337684B (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f.
BRPI1013177A2 (pt) construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
WO2007135546A3 (en) TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
WO2011138557A3 (fr) Utilisation d&#39;anticorps anti-cd71 pour la préparation d&#39;un médicament
WO2009051201A1 (ja) 抗bst2抗体

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880126268.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08857234

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009544756

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2707689

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20107012395

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008332296

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008857234

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008332296

Country of ref document: AU

Date of ref document: 20081205

Kind code of ref document: A